We are live on ! Find out more
PRQR icon

ProQR Therapeutics

30 hedge funds and large institutions have $123M invested in ProQR Therapeutics in 2014 Q3 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
+30
Holders Change %
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
30
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$415K +$387K +24,148 New
SCM
27
Sterling Capital Management
North Carolina
$333K +$311K +19,380 New
Morgan Stanley
28
Morgan Stanley
New York
$272K +$254K +15,845 New
CLM
29
ClearBridge LLC (Maryland)
Maryland
$58K +$54.5K +3,400 New
SM
30
Sabby Management
Florida
$6.55K +$6.11M +381,249 New

PRQR Hedge Fund Activity: Q3 2014 in Review

30 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2014, worth a combined $123M.

Buyers outnumbered sellers: 30 funds opened new PRQR positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $15.2M.

  • 30 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2014, up from 0 in Q2 2014.
  • Funds reported $123M of ProQR Therapeutics stock for Q3 2014.
  • 30 funds opened new ProQR Therapeutics positions in Q3 2014 and 0 closed out, a net change of +30 holders.
  • The largest ProQR Therapeutics buyer in Q3 2014 was OrbiMed, an estimated $15.2M added.

Based on aggregated 13F filings for Q3 2014.